AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor entering a Phase 1 clinical trial in acute kidney injury (AKI) associated with cardiac surgery, in the first half of 2026.

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

IgA nephropathy, an immune assault on the kidneys, is often missed. New treatments mean that spotting it sooner might save lives ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

Your autonomic nervous system helps regulate emotional balance, but chronic stress or trauma can trigger an overactive fight-or-flight response. Nervous system dysregulation refers to a condition in ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own tissues. The protein, called granzyme K, whose role until now was unclear, ...